58 results about "Middle cerebral artery" patented technology

Systems and methods for determining ICP based on parameters that can be measured using non-invasive or minimally invasive techniques are provided, wherein a non-linear relationship is used to determine ICP based on one or more variable inputs. The first variable input relates to one or more properties of a cranial blood vessel and/or blood flow, such as acoustic backscatter from an acoustic transducer having a focus trained on a cranial blood vessel, flow velocity in a cranial blood vessel, and the like. Additional variables, such as arterial blood pressure (ABP), may be used in combination with a first variable input relating to one or more properties of a cranial blood vessel, such as flow velocity of the middle cerebral artery (MCA) to derive ICP using a non-linear relationship. Methods and systems for locating target areas based on their acoustic properties and for acoustic scanning of an area, identification of a target area of interest based on acoustic properties, and automated focusing of an acoustic source and/or detector on a desired target area are also provided. Acoustic transducer assemblies are described.

A method of transcranial ultrasound thrombolysis comprises the steps of providing a predetermined level of ultrasonic energy substantially throughout a primary treatment zone encompassing the M1 branch and M2 branches of the middle cerebral artery of an individual. A thrombolytic agent is also administered to the individual. A transcranial ultrasound thrombolysis system (10) is also provided that includes a transducer (20). The transducer is adapted to provide a predetermined level of ultrasonic energy substantially throughout a primary treatment zone encompassing at least a substantial portion of the M1 branch and the M2 branches of the middle cerebral artery in one hemisphere of a brain.

A suction catheter system is described with a suction extension interfaced with a guide catheter to form a continuous suction lumen extending through a portion of the guide catheter and through the suction extension. The suction extension can be positioned by tracking the suction nozzle through a vessel while moving a proximal portion of the suction extension within the lumen of the guide catheter. The suction extension can comprise a connecting section with a non-circular cross section for interfacing with the inner lumen of an engagement section of the guide catheter. The tubular body of the guide catheter can have a reduced diameter distal section the can be useful to restrain the movement of the suction extension.

A method is provided for noninvasive, continuous, real-time monitoring of a patient's arterial blood pressure using Doppler probes and a blood pressure cuff for measurement of a patient's systolic and diastolic blood pressures at a major distal artery. A continuous Doppler blood flow velocity measurement is used to generate a waveform signal correlating to a cuff's measurements of systolic and diastolic pressures. In addition, a method determines cerebral blood perfusion by providing at least two Doppler probes, one of which is placed at a distal artery with a blood pressure cuff and another of which is placed over the carotid artery or the middle cerebral artery. An algorithm calculates systolic and diastolic pressures at the distal artery and at the carotid artery or the middle cerebral artery as a function of the continuously measured Doppler blood flow velocities.

The invention relates to a method for establishing an artery ischemia model of a brain of a rhesus monkey and an evaluation method. The constructing method adopts the mode of directly puncturing femoral arteries of an experimental monkey to perform the intravascular interventional operation under the direct view of a digital subtraction angiography, and establishes the chronic cerebral infarctionprimate model by using a micro-catheter to block the arteries in the brain of the experimental monkey and controlling ischemia time. The model is a quite reasonable cerebral ischemia-reperfusion animal model, and the pathological characteristics of the monkey cerebral injury model established by the method are similar to clinical manifestation; and moreover, the model is stable and reliable and issuitable for all kinds of curing therapeutic research and related basic research.

The invention relates to a system for measuring the conduction time of pulse waves between cerebral arteries and cerebral veins. The system comprises a signal acquisition device, a signal processing device and a display device, wherein the signal acquisition device is connected with the signal processing device through a communication interface module; and the output end of the signal processing device is connected with the display device. The cerebral blood flow signal acquisition method comprises the following steps: 1) arranging a fixed probe device with two cerebral blood flow signal acquisition devices; 2) synchronously acquiring cerebral blood flow signals; and 3) exchanging the positions of the two cerebral blood flow signal acquisition devices. The medicinal uses of the system are as follows: 1) synchronously acquiring the cerebral blood flow signals of ipsilateral encephalic large arteries (aorta) and encephalic deep veins of a person to be tested at a resting state; and 2) measuring the time difference of the two cerebral blood flow signals. Through the system provided by the invention, noninvasive detection is realized on the conduction time of pulse waves between the cerebral arteries and the cerebral veins; and the clinical practicality is strong, the stiffness of cerebral arteriolae can be accurately and directly reflected, and the risk of apoplexy is estimated, thus being beneficial for early discovering and preventing cerebral arteriosclerosis of patients.

The invention relates to novel use of methylene blue (MB) in prevention of acute cerebral ischemia. MB can remarkably reduce cerebral ischemia infarction caused by permanent middle cerebral artery occlusion (middle cerebral artery occlusion MCAO) and alleviate damage of neurological function. The inventors of the invention permanently occlude middle cerebral artery of a mouse by adopting a suture method and after intraperitoneal injection of MB at the moment and at different time points after cerebral ischemia, changes on degree and ethology of permanent cerebral ischemia infarction of the mouse are observed. Researches discover that MB can remarkably reduce infarct volume caused by cerebral ischemia and improve the active ability of the mouse after cerebral ischemia. Through the method provided by the invention, moderate doses of MB are delivered for many times after cerebral ischemia can remarkably alleviate damage degree after permanent cerebral ischemia of the mouse so as to improve the active ability of the mouse after cerebral ischemia. The use of MB is expected to provide a rescue therapeutic measure to cerebral apoplexy and alleviate permanent neurological function deficit after golden treatment period.

The invention provides a preparation method of a permanent middle cerebral artery occlusion model. The preparation method comprises the following steps of: a, selecting a spontaneous hypertension rat; b, establishing the permanent middle cerebral artery occlusion model by utilizing a suture method. The preparation method has the advantages that the suture method is simpler in operation in comparison with sphenotresia; the scheme is practicable in operation, good in repeatability and high in success rate; and the clinical practice can be better fulfilled.

An agent for treating strokes in humans is tested in a non-human subject by selecting an agent for testing and by preparing a selected non-human subject. The preparation includes: inducing a stroke event by advancing a microwire through the arterial system of the subject to a selected intracranial target position, inserting a microcatheter along the microwire and delivering an embolic device to the target position, occluding the artery at the target position by deploying the embolic device, verifying the occlusion and repositioning the embolic device if needed. After a predetermined occlusion interval, reperfusion of the subject is simulated by removing the embolic device and commencing therapy with the selected agent. At appropriate intervals, the effect of the conducted course of therapy is assessed non-invasively until terminal evaluation. In particular aspects, the method involves occluding the middle cerebral artery through an access achieved via the basilar artery.

The invention provides a fetal monitoring device and terminal equipment. The device comprises a data receiving module, a data processing module and a result output module, wherein the data receiving module, from maternal-fetal Doppler flow parameters, is used for receiving a first PI value of fetal middle cerebral artery, a PSV value of the middle cerebral artery, a second PI value of umbilical artery and spectrum characteristics of the umbilical artery, and the data receiving module is used for receiving a VPI value of fetal venous catheter and spectrum characteristics of the venous catheter; the data processing module is used for determining reference information representing a fetal status according to the first PI value and the PSV value, the second PI value and the spectrum characteristics of the umbilical artery, the VPI value and the spectrum characteristics of the venous catheter; and the result output module is used for outputting the reference information onto a user interface. Through the technical scheme disclosed by the invention, the classification for the fetal status can be achieved through the reference information, and the trends of fetal-placental circulation and fetal circulation, which continuously vary along with gestational weeks, can be dynamically observed, so that the credibility of fetal monitoring is improved.

The invention discloses a method for making a guinea pig MCAO (middle cerebral artery occlusion) model, which comprises the steps of preparing an anesthetic, weighing a guinea pig, and injecting a certain amount of the anesthetic into the abdominal cavity according to the weight of the guinea pig, so that the guinea pig is anesthetized; placing the guinea pig on a temperature control blanket, fixing the guinea pig on an operating table with the body of the guinea pig straight and free of tension, scraping the neck hair of the guinea pig with a hair clipper, and locally sterilizing with entoiodine; cutting the skin along the paracervical median of the guinea pig to open the anterior cervical fascia and expose the sternocleidomastoid muscle on the right side, then separating the anterior cervical muscle group and sternocleidomastoid muscle, and drawing with a fine silk thread to separate the muscle tissues until a complete CCA (common carotid artery) is observed. Compared with the traditional common carotid artery plug-in method, the method has the advantages that blood is directly supplied from the common carotid artery through the internal carotid artery after reperfusion, the common carotid artery is directly ligated after reperfusion, the reperfusion blood supply can only be circulated through lateral branches, the reperfusion effect similar to the clinical effect can be achieved, and the success rate of model preparation is high.

The invention belongs to the field of traditional Chinese medicine pharmacy, and relates to the application of the specific monomer leonurine in the Chinese herbal medicine motherwort in the preparation of pharmaceutical compositions, especially the application in the preparation of medicines for preventing and treating ischemic stroke. The present invention studies the middle cerebral artery occlusion experimental model through craniotomy, and the results show that the motherurine can improve the activity of glutathione peroxidase and superoxide dismutase; reduce lipid peroxidation products The level of malondialdehyde can reduce the size of cerebral infarction; increase the expression of Bcl-2 and reduce the expression of Bax protein; reduce the degree of mitochondrial swelling and increase the level of membrane potential. The result proves that said motherwortine has obvious protective effect on ischemic brain tissue, and can be used to prepare medicines for preventing and treating ischemic apoplexy.

The invention discloses application of epicannabidiol hydrate in preparing drugs for preventing and/or curing brain injuries and a pharmaceutical composition comprising the epicannabidiol hydrate. According to the application of the epicannabidiol hydrate in preparing the drugs for preventing and/or curing the brain injuries, it is the first time to discover that the epicannabidiol hydrate has a drug effect of obviously relieving a brain injury caused by a cerebral ischemic stroke. Researches show that the epicannabidiol hydrate relieves in vitro and vivo neural inflammatory reactions by inhibiting expression of a proinflammatory factor and promoting expression of an anti-inflammatory factor, has a function of obviously decreasing the volume of cerebral infarction after transient middle cerebral artery occlusion, relieves inflammatory overreactions of ischemic brain tissue, and realizes a neuroprotective effect after cerebral ischemia, and can be effectively applied to preventing and/or curing the brain injuries, especially the brain injury caused by the cerebral ischemic stroke; and the pharmaceutical composition comprising the epicannabidiol hydrate can become a novel drug for preventing and/or curing the brain injuries of brain diseases closely associated with brain inflammations, and various brain diseases can be cured.

The invention belongs to the technical field of medicine and pharmacology, and discloses a drug for treating cerebral apoplexy and a construction method of an endogenous stem cell expression animal model, and the drug for treating cerebral apoplexy is liver-softening collateral-dredging decoction. The number of rat brain tissue BrdU, BrdU/NeuN and BrdU/GFAP positive cells in each group at each time point is detected through an ischemia reperfusion model caused by middle cerebral artery occlusion, and the influence of the liver softening and collateral dredging soup on proliferation and differentiation of endogenous neural stem cells of rats with ischemic brain injury is analyzed. According to the method, an improved Longa method is adopted to manufacture an ischemia-reperfusion brain injury model caused by MCAO type middle cerebral artery occlusion of rats; it is verified that the liver-softening collateral-dredging decoction promotes proliferation of endogenous neural stem cells of ischemia-reperfusion brain injury rats, differentiates the endogenous neural stem cells into mature neurons, inhibits excessive proliferation of astrocytes, promotes nerve regeneration and repair and improves nerve functions.

The embodiment of the invention discloses a typing method, device and equipment, and belongs to the technical field of medical images and computers. The method comprises the following steps: acquiringto-be-processed image data; preprocessing the to-be-processed image data to obtain preprocessed image data; and based on a convolution module, a global feature fusion module and a classification module, carrying out typing on the preprocessed image data to obtain a typing result of the to-be-processed image data, the convolution module comprising a first convolution module and a second convolution module. By adopting the method provided by the embodiment of the invention, the non-acute occlusion imaging diagnosis of the middle cerebral artery can be quickly, comprehensively and accurately carried out, the typing of the cerebral infarction or the scoring of the cerebral infarction, such as ASPECTS scoring, can be realized, and a reference basis is provided for clinical treatment.

The invention discloses interferon regulatory factor 9 (IRF9) and application of an inhibitor thereof in cerebral apoplexy, belonging to the field of gene function and application. The invention uses IRF9 gene knock-out mice and brain-specific IRF9 transgenic mice as experimental subjects and adopts middle cerebral artery ischemia reperfusion model, results show that compared with mild type C57 mouse, the brain infarction volume of IRF9 gene knock-out mouse is apparently inhibited, and nerve function is improve remarkably, while the infarction volume of nerve-specific IRF9 transgenic mouse is apparently inhibited, and nerve function is deteriorated markedly. Therefore, IRF9 gene has nervous system function deterioration effect; especially, IRF9 gene can deteriorate cerebral apoplexy. As for the above function of IRF9, the invention provides application of IRF9 as drug target of cerebral apoplexy treatment in developing medicaments for treating cerebral apoplexy.

The invention discloses a method for establishing a mouse middle cerebral artery remote ischemia reperfusion model, and belongs to the technical field of experimental animal models. According to the method, one line and a middle cerebral artery remote blood vessel are tied together in parallel for ligating to achieve blockage of the middle cerebral artery remote blood vessel, line releasing is conducted after blockage is conducted for 50 min, according to the method, the risk of damaging the blood vessel is reduced, blockage of the blood vessel can be well achieved, subsequent reperfusion is facilitated, according to the method, time for establishing a transient dMCAO model of a mouse is shortened, the modeling cost is reduced, the ischemia reperfusion model of dMCAO can be stably and effectively realized, repeatability is good, and a death rate is low.

The invention provides a trocar applied to middle cerebral artery occlusion models, and belongs to the field of medical apparatus and instruments. The trocar can be recycled and comprises a puncture needle, a core and a suture. The puncture needle comprises a needle, a fixing wing and a fixing connector, the fixing wing is fixed to a side surface of the needle, the tapered top of the fixing connector is connected with the bottom of the needle, and a tapered opening is formed in the bottom of the fixing connector; the core comprises a core body and a fixing interface, and the taper of the tapered top of the fixing interface is identical to the taper of the opening in the bottom of the fixing connector, so that the fixing interface can assuredly cling to the fixing connector; the core is used for fixing the integral trocar, and effects of stopping bleeding and preventing the puncture needle from penetrating blood vessels can be realized; the suture is of a commercially available structure. The trocar has the advantages that the puncture needle is used for being arranged in the blood vessels, the core can be pushed into the puncture needle, the puncture needle can be prevented from piecing the blood vessels, and the suture can be inserted into the core and can penetrate the core to reach target blood vessel locations; the trocar is simple in structure and low in manufacturing cost, and can be conveniently and quickly operated, the puncture needle can be arranged in the blood vessels and can be simultaneously fixed, and accordingly bleeding can be stopped by means of blocking.

The invention relates to application of a medicine taking alpha-asarone as a unique pharmacological active component in treatment of cerebral arterial thrombosis. The medicine provided by the invention can be used for effectively treating cerebral arterial thrombosis and has no obvious toxic or side effect. The medicine can obviously increase the blood flow ratio of the infarct side half brain to the opposite side half brain of a middle cerebral artery occlusion ischemia reperfusion rat and reduce the cerebral infarction volume; the nerve function score is obviously improved, and the lifetime of the model rat is prolonged; the occurrence rate of epilepsy caused by cerebral arterial thrombosis is obviously reduced.

The invention relates to a method for photochemically inducing a macaque cerebral stroke model. The method comprises the following steps: (1) intravenously injecting 20mg/kg of rose-bengal; and (2) respectively continuously illuminating three parts at a far end of a middle cerebral artery of the macaque for 20 minutes. By utilizing the method for continuously carrying out photochemical induction on three brain parts of the macaque, the durably injured macaque cerebral stroke model is constructed, the operation is easy, a durable modeling effect is achieved, a macaque is slightly injured by themacaque cerebral stroke model, the fatality rate is low, and the method is used for researching pathogenesis and treatment strategies of the cerebral stroke and has important significances to research of preclinical experiments for the cerebral stroke.

The invention discloses application of medioresinol in preparation of a drug for preventing or treating the cerebral injury and a pharmaceutical composition thereof. The invention provides applicationof medioresinol in preparation of a drug for preventing or treating the cerebral injury for the first time; the medioresinol has an obvious effect on prevention or treatment of the cerebral injury, especially the cerebral injury caused by the cerebral arterial thrombosis; and the cerebral injury caused by the cerebral arterial thrombosis can be obviously reduced. The experiment discovers that themedioresinol has an effect of inhibiting brain microvascular endothelial cell damage caused by oxygen-glucose deprivation and is capable of obviously reducing the permeability of a blood brain barrier under oxygen-glucose deprivation. The medioresinol can reduce the volume of cerebral infarction under middle cerebral artery occlusion remarkably. The pharmaceutical composition containing the medioresinol can become a novel drug for preventing and/or treating the cerebral injury and is used for treating various cerebrovascular diseases including cerebral arterial thrombosis.

The invention discloses application of axitinib and analogues in preparing an anti-ischemic cerebral stroke medicine. According to the invention, the treatment effect of axitinib on ischemic cerebral stroke is evaluated, and it is found that axitinib can reduce the cerebral ischemia infarction volume of middle cerebral artery occlusion and reperfusion model rats, relieve cerebral edema and improve dyskinesia; and axitinib can also slow down the apoptosis state of bEnd.3 cerebrovascular cells under the oxygen-glucose deprivation condition. Therefore, the axitinib and the analogue thereof can be used for preparing the anti-ischemic cerebral stroke medicine.